Azabicyclic ether derivatives and their use as therapeutic agents
    2.
    发明授权
    Azabicyclic ether derivatives and their use as therapeutic agents 失效
    偶氮二环醚衍生物及其作为治疗剂的用途

    公开(公告)号:US06727249B2

    公开(公告)日:2004-04-27

    申请号:US10113117

    申请日:2002-04-01

    IPC分类号: A61K31535

    CPC分类号: C07D451/02

    摘要: The present invention relates compounds of the formula (I): wherein X represents hydrogen, C1-4alkyl optionally substituted by a hydroxy, methoxy or benzyloxy group, or CO2(C1-2alkyl); Z is —CR9R10CH2— or —CH2CR9R10—; and R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migaine, emesis or postherpetic neuralgia.

    摘要翻译: 本发明涉及式(I)化合物:其中X代表氢,任选被羟基,甲氧基或苄氧基取代的C 1-4烷基或CO 2(C 1-2烷基); Z是-CR 9 R 10 CH - 或-CH 2 CR 9 R 10 - ,R 1,R 2,R 3,R 4,R 5和R 6如本文所定义。化合物 特别用于治疗或预防抑郁,焦虑,疼痛,炎症,迁移物,呕吐或带状疱疹后神经痛。

    Benzofuran derivatives as D.sub.4 receptor antagonists
    5.
    发明授权
    Benzofuran derivatives as D.sub.4 receptor antagonists 失效
    苯并呋喃衍生物作为D4受体拮抗剂

    公开(公告)号:US5665722A

    公开(公告)日:1997-09-09

    申请号:US732255

    申请日:1996-10-18

    摘要: A class of chemical compounds comprising a benzo [b] furan moiety and a substituted heterocyclic moiety, linked via the 3-position of the benzo [b] furan moiety by a methylene group, are antagonists of dopamine receptor subtypes within the brain, being extremely potent antagonists of the human dopamine D.sub.4 subtype over other dopamine receptor subtypes, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia while manifesting fewer side-effects than those associated with classical neuroleptic drugs.

    摘要翻译: PCT No.PCT / GB95 / 00947 Sec。 371日期:1996年10月18日 102(e)日期1996年10月18日PCT提交1995年5月26日PCT公布。 出版物WO95 / 29911 日期:1995年11月9日一类包含苯并[b]呋喃部分和取代的杂环部分的化合物,通过苯并[b]呋喃部分的3-位被亚甲基连接,是多巴胺受体亚型的拮抗剂 脑是人类多巴胺D4亚型与其他多巴胺受体亚型相当的非常有效的拮抗剂,因此在治疗和/或预防精神病性障碍如精神分裂症方面有益,而与古典神经安定药物相关的副作用较少 。